RAC 2.20% $1.78 race oncology ltd

Ann: Race Strategic Update March 2021, page-279

  1. 2,725 Posts.
    lightbulb Created with Sketch. 10552
    Your first point I think is a very interesting one. Yesterday we announced something new (Israeli AML trial about to start) that was not known to the market and brings forwards our next lot of clinical results by more than 6 months. We will have results from patients in that trial from around the middle of the year.

    In regards Pillar 2 (breast cancer) we had only indicated prior to yesterday that we would be releasing the results of the George Clinical review. Instead we announced that we have a clinical trial already underway.

    In regards the EMD AML trial we had just announced we would report if it was viable or not. Instead we announced that we had a clinical trial underway with first patient results expected from this year.

    I am curious to know what people were expecting?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.